Novan Inc was incorporated in January 2006 under the state laws of Delaware. The Company together with its subsidiaries is a North Carolina based clinical-stage drug development company. It is engaged in the development and commercialization of nitric oxide-based therapies in dermatology. The Company's products candidates include SB204 for the Treatment of Acne Vulgaris, SB206, a Topical Anti-viral for the Treatment of External Genital and Perianal Warts, SB208, a Topical Anti-fungal for the Treatment of Onychomycosis, and SB414, a Topical Anti-inflammatory for the Treatment of Inflammatory Skin Diseases. The Company manufactures Nitricil NCEs at its facility in Durham, North Carolina for all product candidates. The Company faces competition from number of sources, such as pharmaceutical companies, generic drug companies, biotechnology companies and academic and research institutions. The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs, such as those it is developing.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.